CLINICAL_TRIALS
trial_result
· 2007-02-27
Clinical Trial Update: Cabergoline Reduces OHSS [Phase 3]
Summary
Phase 3 trial results indicate that cabergoline reduces the risk of ovarian hyperstimulation syndrome in patients undergoing fertility treatment.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA | Conditions: Ovarian Hyperstimulation Syndrome | Phase 3 | Status: COMPLETED